Torcetrapib's failure raises new questions
Marc Iskowitz,Stephen McGuire
January 01 2007
The halt of Pfizer's torcetrapib program has potentially far-reaching implications for the broader industry and raises questions about safety of ...
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.